Fig. 1From: Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edemaMean central macular thickness (CMT) change in all three groups of patients in follow up visits (upper linear graphs) and also in patients with baseline CMT > 400 microns (lower linear graphs). CMT, central macular thickness, IVB, intravitreal bevacizumab, INF, Interferon alpha 2bBack to article page